Algert Global LLC Purchases 848 Shares of Eli Lilly and Company $LLY

Key Points

• Algert Global LLC increased its holdings in Eli Lilly and Company by 6.9%, owning 13,106 shares valued at approximately $10.82 million.
• Insider transactions included CEO David A. Ricks purchasing 1,632 shares at $644.77 each, increasing his ownership stake, while EVP Daniel Skovronsky bought 1,000 shares at $634.40.
• Several analysts updated their ratings on Eli Lilly, with DZ Bank upgrading the stock to a "strong-buy", while the average price target has decreased from $1,010 to $900.

Algert Global LLC grew its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 6.9% during the first quarter, according to its most recent filing with the SEC. The firm owned 13,106 shares of the company's stock after acquiring an additional 848 shares during the period. Algert Global LLC's holdings in Eli Lilly and Company were worth $10,824,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Knightsbridge Asset Management LLC raised its holdings in Eli Lilly and Company by 1.9% during the fourth quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock valued at $628,000 after acquiring an additional 15 shares during the period. Corient IA LLC acquired a new position in shares of Eli Lilly and Company in the 1st quarter valued at $570,000. LS Investment Advisors LLC grew its position in Eli Lilly and Company by 1.7% during the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after purchasing an additional 40 shares during the period. Prism Advisors Inc. acquired a new stake in shares of Eli Lilly and Company during the 1st quarter valued at about $207,000. Finally, CSM Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 30.6% during the 4th quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock worth $807,000 after purchasing an additional 245 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Insider Activity

In other Eli Lilly and Company news, Director J Erik Fyrwald bought 1,565 shares of the stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director directly owned 74,578 shares of the company's stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Daniel Skovronsky acquired 1,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the purchase, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. This trade represents a 0.73% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 4,514 shares of company stock worth $2,894,841. Company insiders own 0.13% of the company's stock.

Wall Street Analyst Weigh In

LLY has been the subject of several research analyst reports. Morgan Stanley restated an "overweight" rating and issued a $1,135.00 price objective (up previously from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. HSBC downgraded shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their target price for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. Cantor Fitzgerald reduced their target price on shares of Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a research note on Wednesday, August 13th. Leerink Partners reaffirmed a "market perform" rating and issued a $715.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Finally, DZ Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $950.17.

Eli Lilly and Company Stock Performance

NYSE LLY traded up $7.4150 on Thursday, hitting $712.8550. 2,347,611 shares of the stock were exchanged, compared to its average volume of 4,167,736. The company has a market capitalization of $674.69 billion, a PE ratio of 46.59, a P/E/G ratio of 0.98 and a beta of 0.44. The business's fifty day moving average is $758.91 and its 200 day moving average is $792.41. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $972.53. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company's revenue was up 37.6% compared to the same quarter last year. During the same period in the prior year, the company posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's payout ratio is currently 39.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.